News and Press Releases
Press releases
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Press ReleaseNewsfile | Dec 23, 2025 4:40 PM EST Toronto, Ontario–(Newsfile Corp. – December 23, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering lig...
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Press ReleaseNewsfile | Dec 12, 2025 5:00 PM EST Toronto, Ontario–(Newsfile Corp. – December 12, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering lig...
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleaseNewsfile | Nov 24, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 24, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering lig...
Theralase® Investor Conference Call Reminder
Press ReleaseNov 17, 2025 7:00 AM EST Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response Toronto, Ontario–(Newsfile Corp. – November 17, 2025) – Theralase® Technologies ...
Theralase® Releases 3Q2025 Financial Statements
Press ReleaseNov 10, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 10, 2025) – Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound ...
Theralase® Demonstrates Effectiveness of X-Ray-Activated Drug
Press ReleaseNov 3, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 3, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation...
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Press ReleaseSep 24, 2025 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – September 24, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiat...
Theralase® Extends Warrants
Press ReleaseAug 29, 2025 4:30 PM EDT Toronto, Ontario–(Newsfile Corp. – August 29, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation...
Theralase® Releases 2Q2025 Financial Statements
Press ReleaseToronto, Ontario–(Newsfile Corp. – August 26, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therap...
Theralase® Extends Warrants
Press ReleaseTheralase® Technologies Inc. plans to extend the expiry date of 4,800,000 share purchase warrants from June 30, 2025, to June 30, 2028. The warrants, issued in 2023, remain exercisable at $0.35 per share under the same terms. The...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
